3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms by Histologic Type
2
Myeloproliferative Disorders
2
Leukemia, Myeloid
2
Hematologic Diseases
2
Bone Marrow Diseases
2
Small Cell Lung Carcinoma
1
Piebaldism
1
Malignant Hepatobiliary Neoplasm
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Blast Crisis
1
Adenocarcinoma of Lung
1
Interventions
Oxaliplatin
14
Fluorouracil
11
Capecitabine
9
Surveys and Questionnaires
8
Leucovorin
8
Irinotecan
8
Cisplatin
8
Bevacizumab
8
Standard of Care
5
Gemcitabine
5
Drug Therapy
4
S 1 (combination)
3
Radiotherapy
3
Nivolumab
3
Interviews as Topic
3
IFL protocol
3
Educational Status
3
Cyclophosphamide
3
Colonoscopy
3
Blood Specimen Collection
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
tivozanib
2
pembrolizumab
2
Taxes
2
Remote Patient Monitoring
2
Pemetrexed
2
Panitumumab
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Neoplasms
×
ponatinib
×
Clear all
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts